LFCR Stock Overview
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Lifecore Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.53 |
| 52 Week High | US$11.46 |
| 52 Week Low | US$3.78 |
| Beta | 1.06 |
| 1 Month Change | -9.05% |
| 3 Month Change | -2.10% |
| 1 Year Change | 67.44% |
| 3 Year Change | -41.54% |
| 5 Year Change | -37.27% |
| Change since IPO | -48.78% |
Recent News & Updates
Recent updates
Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?
Jun 30
Landec Non-GAAP EPS of -$0.32, revenue of $43.35M
Oct 06Landec receives Nasdaq's notification on delayed annual report filing
Sep 09Laughing Water Capital - Landec Corp. : A High Quality CDMO
Jul 27Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt
Jun 24Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report
Apr 08Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet
Mar 21Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital
Nov 30Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products
Nov 05Landec Still In Play As An Activist Investment
Aug 20Is Landec (NASDAQ:LNDC) Using Too Much Debt?
May 25Is Landec (NASDAQ:LNDC) Using Too Much Debt?
Feb 24The CEO, President & Director of Landec Corporation (NASDAQ:LNDC), Albert Bolles, Just Bought 38% More Shares
Jan 20
Shareholder Returns
| LFCR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 11.6% | -6.3% | -3.5% |
| 1Y | 67.4% | -6.3% | 20.2% |
Return vs Industry: LFCR exceeded the US Life Sciences industry which returned -6.3% over the past year.
Return vs Market: LFCR exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| LFCR volatility | |
|---|---|
| LFCR Average Weekly Movement | 12.8% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LFCR's share price has been volatile over the past 3 months.
Volatility Over Time: LFCR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 459 | Jim Hall | www.lifecore.com |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products.
Lifecore Biomedical, Inc. Fundamentals Summary
| LFCR fundamental statistics | |
|---|---|
| Market cap | US$199.78m |
| Earnings (TTM) | -US$64.24m |
| Revenue (TTM) | US$103.27m |
1.9x
P/S Ratio-3.1x
P/E RatioIs LFCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LFCR income statement (TTM) | |
|---|---|
| Revenue | US$103.27m |
| Cost of Revenue | US$75.28m |
| Gross Profit | US$27.99m |
| Other Expenses | US$92.22m |
| Earnings | -US$64.24m |
Last Reported Earnings
May 28, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.10 |
| Gross Margin | 27.10% |
| Net Profit Margin | -62.20% |
| Debt/Equity Ratio | 474.6% |
How did LFCR perform over the long term?
See historical performance and comparison